Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 14, 2010; 16(38): 4865-4870
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4865
Figure 1
Figure 1 Left artery blood flow response to different doses of amino-acid substituted pituitary adenylate cyclase-activating polypeptide-27 analogues. PACAP: Pituitary adenylate cyclase-activating polypeptide; VIP: Vasoactive intestinal polypeptide.
Figure 2
Figure 2 Effects of different doses of amino-acid substituted pituitary adenylate cyclase-activating polypeptide-27 analogues, pituitary adenylate cyclase-activating polypeptide-27 and vasoactive intestinal polypeptide on left artery blood flow. aP < 0.05, bP < 0.01 vs pituitary adenylate cyclase-activating polypeptide (PACAP)-27; cP < 0.05, dP < 0.01 vs vasoactive intestinal polypeptide (VIP). LGA: Left gastric artery.
Figure 3
Figure 3 Effects of C-terminal deletions in pituitary adenylate cyclase-activating polypeptide-38 and pituitary adenylate cyclase-activating polypeptide-27 on left artery blood flow (mean ± SE). PACAP: Pituitary adenylate cyclase-activating polypeptide; LGA: Left gastric artery.